EU approves Schering-Plough's anesthetic-reversal drug

07/30/2008 | Bloomberg1

The EU cleared Schering-Plough's sugammadex for use in reversing the effects of anesthesia -- particularly a muscle relaxant called recuronium -- in patients who underwent surgery. The drug, which awaits FDA approval, will be sold under the brand Bridion.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC